ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00544180

Enrollment

Registered

2007-10-16

Start date

2005-05-31

Completion date

Unknown

Last updated

2009-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.

Interventions

DRUGRisedronate

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

55 Years to 80 Years

Healthy volunteers

Inclusion criteria

: * Postmenopausal ambulatory women * Established osteoporosis

Exclusion criteria

* History of cancer: basal cell or squamous cell carcinoma-documented 6-month remission, * Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Design outcomes

Primary

Measure	Time frame
Patient satisfaction and compliance	During all the study

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026